Skip to content
OpenCapital
Get started

Cytokinetics CYTK Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
——
Medtronic logo
MedtronicMDT
——

Other financials

Income statement

See full
Revenue$19.4M+1,126%
Operating income-$183.6M-18.0%
Net income-$206.0M-27.7%
EPS (diluted)-$1.67-22.8%

Balance sheet

See full
Cash & equivalents$129.8M+76.2%
Total debt$418.2M+75.8%
Total equity-$826.6M-210%
Total assets$1.3B+0.7%

Cash flow

See full
Operating cash flow-$145.5M-10.5%
CapEx$5.9M+4.7%
Free cash flow-$151.4M-10.3%

Valuation

See full
Market cap$10.7B+70.6%
Enterprise value$10.98B+70.7%
P/S101.1×-225×

Profitability

See full
Operating margin-605.1%-268pp
Net margin-784%-337pp
FCF margin-518.8%-223pp

Returns & leverage

See full
Return on equity-337.6%—
Debt / equity2.2×—
Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytokinetics's cash provided by (used in) financing activity, including discontinued operation?
Cytokinetics (CYTK) reported cash provided by (used in) financing activity, including discontinued operation of $7.77M in Q1 2026.
How has Cytokinetics's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
Cytokinetics's cash provided by (used in) financing activity, including discontinued operation increased by 63.4% year-over-year, from $4.75M to $7.77M.
What is the long-term trend for Cytokinetics's cash provided by (used in) financing activity, including discontinued operation?
Over 4 years (2021 to 2025), Cytokinetics's cash provided by (used in) financing activity, including discontinued operation has grown at a 13.1% compound annual growth rate (CAGR), from $319.98M to $524.46M.